Third-Trimester HIV Viremia Treated With Long-Acting Cabotegravir and Rilpivirine: A Case Report

TL;DR

A pregnant individual experienced a rapid drop in HIV levels using long-acting injectable drugs during the third trimester.

Contribution

This is the first case to show significant HIV viral load reduction using long-acting injectables during pregnancy.

Findings

Long-acting cabotegravir and rilpivirine reduced HIV viral load rapidly in the third trimester.

The case highlights challenges with daily oral HIV therapy during pregnancy.

Abstract

We report the first case to quantitatively demonstrate a rapid and substantial viral load reduction using long-acting cabotegravir and rilpivirine in the third trimester of pregnancy. This case underscores the challenges some pregnant individuals face with daily oral antiretroviral therapy and the potential role of long-acting injectables in select scenarios.

Figures